Furci Fabiana, Caminati Marco, Senna Gianenrico, Gangemi Sebastiano
School and Operative Unit of Allergy and Clinical Immunology, Policlinico "G. Martino", Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Department of Medicine, University of Verona and Verona University Hospital, Verona, Italy.
Clin Mol Allergy. 2021 Nov 1;19(1):19. doi: 10.1186/s12948-021-00159-4.
The observation of patients hospitalized for coronavirus disease (COVID-19) led us to note a lower prevalence of patients affected by chronic respiratory disease, in particular asthmatic patients, compared to the general population. Therefore, the aim of this paper is to evaluate the possible protective role of corticosteroid therapy in patients with chronic lung disease, regarding the risk of contracting severe COVID-19.
SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) receptors to enter the cells. Considering the high number of these receptors in patients affected by asthma and chronic obstructive pulmonary disease (COPD), the evidence that these patients do not have a high risk of hospitalization for COVID-19 needs further study to understand what the possible protective "factors" are in these patients. In particular, the finding in some studies of reduced coronavirus replication in cell lines treated with steroids, molecules commonly used for treating chronic lung diseases, needs further attention.
The hypothesis that corticosteroids, commonly used in treating airways diseases, might modify the severity of SARS-CoV-2 disease has become a key point and a possible predictive factor of a positive outcome of COVID-19 in patients treated everyday with these molecules.
对因冠状病毒病（COVID-19）住院患者的观察使我们注意到，与普通人群相比，受慢性呼吸道疾病影响的患者，特别是哮喘患者的患病率较低。因此，本文的目的是评估皮质类固醇疗法在慢性肺病患者中对于感染严重COVID-19风险的可能保护作用。
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）利用血管紧张素转换酶2（ACE2）受体进入细胞。鉴于哮喘和慢性阻塞性肺疾病（COPD）患者体内这些受体数量众多，这些患者感染COVID-19后住院风险不高这一证据需要进一步研究，以了解这些患者中可能存在的保护性“因素”是什么。特别是，一些研究发现，在使用常用于治疗慢性肺病的类固醇处理的细胞系中，冠状病毒复制减少，这一发现需要进一步关注。
常用于治疗气道疾病的皮质类固醇可能改变SARS-CoV-2疾病严重程度这一假设，已成为一个关键点，并且对于每天使用这些药物治疗的患者而言，可能是COVID-19预后良好的一个预测因素。
